Oral transmucosal drug delivery for pediatric use

Advanced Drug Delivery Reviews

Volumn 73, Issue , 2014, Pages 50-62

  Lam, Jenny K W ^a   Xu, Yingying ^a   Worsley, Alan ^a   Wong, Ian C K ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Buccal; Mucoadhesive; Mucosal delivery; Pediatric; Sublingual

Indexed keywords

BIOCHEMISTRY; DRUG DELIVERY; METABOLISM; PHYSIOLOGY;

BUCCAL; GASTROINTESTINAL TRACT; MUCOADHESIVE; MUCOSAL DELIVERY; ORAL BIOAVAILABILITIES; PEDIATRIC POPULATION; PHYSIOLOGICAL PROPERTIES; SUBLINGUAL;

PEDIATRICS;

ANALGESIC AGENT; BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; CELLULOSE ESTER DERIVATIVE; CLONAZEPAM; DIAZEPAM; EXCIPIENT; FENTANYL CITRATE; GLYCERYL TRINITRATE; GRASS POLLEN VACCINE; LORAZEPAM; MACROGOL; MIDAZOLAM; MORPHINE SULFATE; NICOTINE; NICOTINE GUM; NIFEDIPINE; ONDANSETRON; ORALAIR; OXYCODONE; PENETRATION ENHANCING AGENT; POLYACRYLIC ACID; POLYACRYLIC ACID DERIVATIVE; POLYMER; POLYMETHACRYLIC ACID DERIVATIVE; PROCHLORPERAZINE MALEATE; UNCLASSIFIED DRUG; ZOLPIDEM TARTRATE; DRUG; BENZODIAZEPINE DERIVATIVE; CHITOSAN; CYCLODEXTRIN; FENTANYL; INFLUENZA VACCINE; NARCOTIC ANALGESIC AGENT; POLLEN EXTRACT; PROCHLORPERAZINE; VIRUS LIKE PARTICLE VACCINE; ZOLPIDEM;

DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; EMERGENCY MEDICINE; HUMAN; HYDROPHILICITY; LIQUID; LOZENGE; MOLECULAR WEIGHT; MOUTH CAVITY; MOUTH MUCOSA; MUCOADHESION; MUCOSAL ADMINISTRATION; NONHUMAN; ORAL FILM; PRIORITY JOURNAL; REVIEW; SALIVA; SUBLINGUAL IMMUNOTHERAPY; TABLET; TABLET FORMULATION; VACCINATION; WAFER; CHILD; GASTROINTESTINAL ABSORPTION; MEDICINAL CHEMISTRY; METABOLISM; ORAL DRUG ADMINISTRATION; AGE DISTRIBUTION; ALLERGIC RHINITIS; CANCER PAIN; CONJUNCTIVITIS; DRUG FORMULATION; EPILEPTIC STATE; MORPHOLOGY; MUCOSAL DRUG ADMINISTRATION; MUCUS; NAUSEA; OPIATE ADDICTION; PAIN; PAPILLOMAVIRUS INFECTION; PEDIATRICS; SEIZURE; TOBACCO DEPENDENCE; VERTIGO; VOMITING;

ADMINISTRATION, MUCOSAL; ADMINISTRATION, ORAL; CHEMISTRY, PHARMACEUTICAL; CHILD; HUMANS; MOUTH MUCOSA; ORAL MUCOSAL ABSORPTION; PHARMACEUTICAL PREPARATIONS;

EID: 84902328223     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2013.08.011     Document Type: Review

References (157)

1. Bartelink I.H., Rademaker C.M., Schobben A.F., van den Anker J.N. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin. Pharmacokinet. 2006, 45:1077-1097.
2. Nunn T., Williams J. Formulation of medicines for children. Br. J. Clin. Pharmacol. 2005, 59:674-676.
3. Patel V.F., Liu F., Brown M.B. Advances in oral transmucosal drug delivery. J. Control. Release 2011, 153:106-116.
4. Pather S.I., Rathbone M.J., Senel S. Current status and the future of buccal drug delivery systems. Expert Opin. Drug Deliv. 2008, 5:531-542.
5. Walker D.M., Teach S.J. Update on the acute management of status epilepticus in children. Curr. Opin. Pediatr. 2006, 18:239-244.
6. Bagan J., Paderni C., Termine N., Campisi G., Lo Russo L., Compilato D., Di Fede O. Mucoadhesive polymers for oral transmucosal drug delivery: a review. Curr. Pharm. Des. 2012, 18:5497-5514.
7. Senel S., Rathbone M.J., Cansiz M., Pather I. Recent developments in buccal and sublingual delivery systems. Expert Opin. Drug Deliv. 2012, 9:615-628.
8. Madhav N.V., Shakya A.K., Shakya P., Singh K. Orotransmucosal drug delivery systems: a review. J. Control. Release 2009, 140:2-11.
9. Satheesh Madhav N.V., Semwal R., Semwal D.K., Semwal R.B. Recent trends in oral transmucosal drug delivery systems: an emphasis on the soft palatal route. Expert Opin. Drug Deliv. 2012, 9:629-647.
10. Hearnden V., Sankar V., Hull K., Juras D.V., Greenberg M., Kerr A.R., Lockhart P.B., Patton L.L., Porter S., Thornhill M.H. New developments and opportunities in oral mucosal drug delivery for local and systemic disease. Adv. Drug Deliv. Rev. 2012, 64:16-28.
11. Squier C.A. The permeability of oral mucosa. Crit. Rev. Oral Biol. Med. 1991, 2:13-32.
12. Ganem-Quintanar A., FalsonRieg F., Buri P. Contribution of lipid components to the permeability barrier of oral mucosa. Eur. J. Pharm. Biopharm. 1997, 44:107-120.
13. Collins L.M., Dawes C. The surface area of the adult human mouth and thickness of the salivary film covering the teeth and oral mucosa. J. Dent. Res. 1987, 66:1300-1302.
14. Watanabe S., Dawes C. Salivary flow rates and salivary film thickness in five-year-old children. J. Dent. Res. 1990, 69:1150-1153.
15. Squier C.A., Hall B.K. The permeability of skin and oral mucosa to water and horseradish peroxidase as related to the thickness of the permeability barrier. J. Invest. Dermatol. 1985, 84:176-179.
16. Castellanos J., Zia H., Rhodes C. Mucoadhesive drug delivery systems. Drug Dev. Ind. Pharm. 1993, 19:143-194.
17. Peppas N.A., Buri P.A. Surface, interfacial and molecular aspects of polymer bioadhesion on soft tissues. J. Control. Release 1985, 2:257-275.
18. Cilurzo F., Selmin F., Minghetti P., Montanari L. The effects of bivalent inorganic salts on the mucoadhesive performance of a polymethylmethacrylate sodium salt. Int. J. Pharm. 2005, 301:62-70.
19. Hao J., Heng P.W. Buccal delivery systems. Drug Dev. Ind. Pharm. 2003, 29:821-832.
20. Bradley R.M. Secretion of saliva. Basic Oral Physiology 1981, 135-150. Year Book Medical Publishers, Inc., Chicago.
21. Tenovuo J. Antimicrobial function of human saliva-how important is it for oral health?. Acta Odontol. Scand. 1998, 56:250-256.
22. Fortes M.B., Diment B.C., Di Felice U., Walsh N.P. Dehydration decreases saliva antimicrobial proteins important for mucosal immunity. Appl. Physiol. Nutr. Metab. 2012, 37:850-859.
23. Dezan C.C., Nicolau J., Souza D.N., Walter L.R. Flow rate, amylase activity, and protein and sialic acid concentrations of saliva from children aged 18, 30 and 42months attending a baby clinic. Arch. Oral. Biol. 2002, 47:423-427.
24. Gutman D., Ben-Aryeh H. The influence of age on salivary content and rate of flow. Int. J. Oral Surg. 1974, 3:314-317.
25. Rotteveel L.J., Jongerius P.H., van Limbeek J., van den Hoogen F.J. Salivation in healthy schoolchildren. Int. J. Pediatr. Otorhinolaryngol. 2004, 68:767-774.
26. Ono K., Morimoto Y., Inoue H., Masuda W., Tanaka T., Inenaga K. Relationship of the unstimulated whole saliva flow rate and salivary gland size estimated by magnetic resonance image in healthy young humans. Arch. Oral Biol. 2006, 51:345-349.
27. Wu K.P., Ke J.Y., Chung C.Y., Chen C.L., Hwang T.L., Chou M.Y., Wong A.M., Hu C.F., Lee Y.C. Relationship between unstimulated salivary flow rate and saliva composition of healthy children in Taiwan. Chang Gung Med. J. 2008, 31:281-286.
28. Sonesson M., Eliasson L., Matsson L. Minor salivary gland secretion in children and adults. Arch. Oral Biol. 2003, 48:535-539.
29. Siqueira W.L., Bermejo P.R., Mustacchi Z., Nicolau J. Buffer capacity, pH, and flow rate in saliva of children aged 2-60months with Down syndrome. Clin. Oral Investig. 2005, 9:26-29.
30. Chaushu S., Chaushu G., Zigmond M., Yefenof E., Stabholz A., Shapira J., Merrick J., Bachrach G. Age-dependent deficiency in saliva and salivary antibodies secretion in Down's syndrome. Arch. Oral Biol. 2007, 52:1088-1096.
31. Granick M.S., Hanna D.C. Management of Salivary Gland Lesions 1992, Williams & Wilkins, Baltimore.
32. Hidas A., Noy A.F., Birman N., Shapira J., Matot I., Steinberg D., Moskovitz M. Oral health status, salivary flow rate and salivary quality in children, adolescents and young adults with ADHD. Arch. Oral Biol. 2011, 56:1137-1141.
33. Davidovich E., Aframian D.J., Shapira J., Peretz B. A comparison of the sialochemistry, oral pH, and oral health status of Down syndrome children to healthy children. Int. J. Paediatr. Dent. 2010, 20:235-241.
34. Aframian D.J., Davidowitz T., Benoliel R. The distribution of oral mucosal pH values in healthy saliva secretors. Oral Dis. 2006, 12:420-423.
35. Ship J.A. Diagnosing, managing, and preventing salivary gland disorders. Oral Dis. 2002, 8:77-89.
36. Vandana K.L., Savitha B. Thickness of gingiva in association with age, gender and dental arch location. J. Clin. Periodontol. 2005, 32:828-830.
37. Shulman J.D. Prevalence of oral mucosal lesions in children and youths in the USA. Int. J. Paediatr. Dent. 2005, 15:89-97.
38. Majorana A., Bardellini E., Flocchini P., Amadori F., Conti G., Campus G. Oral mucosal lesions in children from 0 to 12years old: ten years' experience. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2010, 110:e13-e18.
39. Bessa C.F., Santos P.J., Aguiar M.C., do Carmo M.A. Prevalence of oral mucosal alterations in children from 0 to 12 years old. J. Oral Pathol. Med. 2004, 33:17-22.
40. Odds F.C. Candida and Candidosis 1988, Elsevier Science Health Science Division.
41. Clark's analysis of drugs and poisons 2011, Pharmaceutical Press, London. 4th ed.
42. Xiang J., Fang X., Li X. Transbuccal delivery of 2',3'-dideoxycytidine: in vitro permeation study and histological investigation. Int. J. Pharm. 2002, 231:57-66.
43. Deneer V.H., Drese G.B., Roemele P.E., Verhoef J.C., Lie A.H.L., Kingma J.H., Brouwers J.R., Junginger H.E. Buccal transport of flecainide and sotalol: effect of a bile salt and ionization state. Int. J. Pharm. 2002, 241:127-134.
44. Nielsen H.M., Rassing M.R. Nicotine permeability across the buccal TR146 cell culture model and porcine buccal mucosa in vitro: effect of pH and concentration. Eur. J. Pharm. Sci. 2002, 16:151-157.
45. Mashru R., Sutariya V., Sankalia M., Sankalia J. Transbuccal delivery of lamotrigine across porcine buccal mucosa: in vitro determination of routes of buccal transport. J. Pharm. Pharm. Sci. 2005, 8:54-62.
46. Birudaraj R., Berner B., Shen S., Li X. Buccal permeation of buspirone: mechanistic studies on transport pathways. J. Pharm. Sci. 2005, 94:70-78.
47. Jeal W., Benfield P. Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control. Drugs 1997, 53:109-138.
48. Muijsers R.B., Wagstaff A.J. Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control. Drugs 2001, 61:2289-2307.
49. Bredenberg S., Duberg M., Lennernas B., Lennernas H., Pettersson A., Westerberg M., Nystrom C. In vitro and in vivo evaluation of a new sublingual tablet system for rapid oromucosal absorption using fentanyl citrate as the active substance. Eur. J. Pharm. Sci. 2003, 20:327-334.
50. Streisand J.B., Varvel J.R., Stanski D.R., Le Maire L., Ashburn M.A., Hague B.I., Tarver S.D., Stanley T.H. Absorption and bioavailability of oral transmucosal fentanyl citrate. Anesthesiology 1991, 75:223-229.
51. Nicolazzo J.A., Reed B.L., Finnin B.C. Buccal penetration enhancers-how do they really work?. J. Control. Release 2005, 105:1-15.
52. Baguley D., Lim E., Bevan A., Pallet A., Faust S.N. Prescribing for children - taste and palatability affect adherence to antibiotics: a review. Arch. Dis. Child. 2012, 97:293-297.
53. Davies E.H., Tuleu C. Medicines for children: a matter of taste. J. Pediatr. 2008, 153:599-604. (604 e591-592).
54. Sudhakar Y., Kuotsu K., Bandyopadhyay A.K. Buccal bioadhesive drug delivery-a promising option for orally less efficient drugs. J. Control. Release 2006, 114:15-40.
55. Salamat-Miller N., Chittchang M., Johnston T.P. The use of mucoadhesive polymers in buccal drug delivery. Adv. Drug Deliv. Rev. 2005, 57:1666-1691.
56. Sohi H., Ahuja A., Ahmad F.J., Khar R.K. Critical evaluation of permeation enhancers for oral mucosal drug delivery. Drug Dev. Ind. Pharm. 2010, 36:254-282.
57. Fabiano V., Mameli C., Zuccotti G.V. Paediatric pharmacology: remember the excipients. Pharmacol. Res. 2011, 63:362-365.
58. Breitkreutz J., Boos J. Drug delivery and formulations. Handb. Exp. Pharmacol. 2011, 205:91-107.
59. Arulanantham K., Genel M. Central nervous system toxicity associated with ingestion of propylene glycol. J. Pediatr. 1978, 93:515-516.
60. Pugach S., Pugach I.Z. Overdose in infant caused by over-the-counter cough medicine. South. Med. J. 2009, 102:440-442.
61. Gershanik J., Boecler B., Ensley H., McCloskey S., George W. The gasping syndrome and benzyl alcohol poisoning. N. Engl. J. Med. 1982, 307:1384-1388.
62. Brown W.J., Buist N.R., Gipson H.T., Huston R.K., Kennaway N.G. Fatal benzyl alcohol poisoning in a neonatal intensive care unit. Lancet 1982, 1:1250.
63. Gershanik J.J., Boecler B., George W., Sola A., Leitner M., Kapadia C. The gasping syndrome-benzyl alcohol (Ba) poisoning. Clin. Res. 1981, 29:A895.
64. Breitkreutz J., Boos J. Paediatric and geriatric drug delivery. Expert Opin. Drug Deliv. 2007, 4:37-45.
65. Neves B.G., Farah A., Lucas E., de Sousa V.P., Maia L.C. Are paediatric medicines risk factors for dental caries and dental erosion?. Community Dent. Health 2010, 27:46-51.
66. Neves B.G., Pierro V.S., Maia L.C. Pediatricians' perceptions of the use of sweetened medications related to oral health. J. Clin. Pediatr. Dent. 2008, 32:133-137.
67. Adverse effects of bulk materials. Clinical Pharmacology 1989, 89-120. Marcel-Dekker Inc., New York. M. Weiner, I.L. Bernstein (Eds.).
68. Shojaei A.H., Li X. Mechanisms of buccal mucoadhesion of novel copolymers of acrylic acid and polyethylene glycol monomethylether monomethacrylate. J. Control. Release 1997, 47:151-161.
69. Lele B.S., Hoffman A.S. Mucoadhesive drug carriers based on complexes of poly(acrylic acid) and PEGylated drugs having hydrolysable PEG-anhydride-drug linkages. J. Control. Release 2000, 69:237-248.
70. Grabovac V., Guggi D., Bernkop-Schnurch A. Comparison of the mucoadhesive properties of various polymers. Adv. Drug Deliv. Rev. 2005, 57:1713-1723.
71. Fefelova N.A., Nurkeeva Z.S., Mun G.A., Khutoryanskiy V.V. Mucoadhesive interactions of amphiphilic cationic copolymers based on [2-(methacryloyloxy)ethyl]trimethylammonium chloride. Int. J. Pharm. 2007, 339:25-32.
72. Rossi S., Ferrari F., Bonferoni M.C., Caramella C. Characterization of chitosan hydrochloride-mucin interaction by means of viscosimetric and turbidimetric measurements. Eur. J. Pharm. Sci. 2000, 10:251-257.
73. Albrecht K., Greindl M., Kremser C., Wolf C., Debbage P., Bernkop-Schnurch A. Comparative in vivo mucoadhesion studies of thiomer formulations using magnetic resonance imaging and fluorescence detection. J. Control. Release 2006, 115:78-84.
74. Bernkop-Schnurch A. Thiomers: a new generation of mucoadhesive polymers. Adv. Drug Deliv. Rev. 2005, 57:1569-1582.
75. Casettari L., Vllasaliu D., Lam J.K., Soliman M., Illum L. Biomedical applications of amino acid-modified chitosans: a review. Biomaterials 2012, 33:7565-7583.
76. Leitner V.M., Walker G.F., Bernkop-Schnurch A. Thiolated polymers: evidence for the formation of disulphide bonds with mucus glycoproteins. Eur. J. Pharm. Biopharm. 2003, 56:207-214.
77. Roldo M., Hornof M., Caliceti P., Bernkop-Schnurch A. Mucoadhesive thiolated chitosans as platforms for oral controlled drug delivery: synthesis and in vitro evaluation. Eur. J. Pharm. Biopharm. 2004, 115-121.
78. Bies C., Lehr C.M., Woodley J.F. Lectin-mediated drug targeting: history and applications. Adv. Drug Deliv. Rev. 2004, 56:425-435.
79. Clark M.A., Hirst B.H., Jepson M.A. Lectin-mediated mucosal delivery of drugs and microparticles. Adv. Drug Deliv. Rev. 2000, 43:207-223.
80. Cui C.Y., Lu W.L., Xiao L., Zhang S.Q., Huang Y.B., Li S.L., Zhang R.J., Wang G.L., Zhang X., Zhang Q. Sublingual delivery of insulin: effects of enhancers on the mucosal lipid fluidity and protein conformation, transport, and in vivo hypoglycemic activity. Biol. Pharm. Bull. 2005, 28:2279-2288.
81. Del Valle E.M.M. Cyclodextrins and their uses: a review. Process. Biochem. 2004, 39:1033-1046.
82. Senel S., Hincal A.A. Drug permeation enhancement via buccal route: possibilities and limitations. J. Control. Release 2001, 72:133-144.
83. Senel S., Duchene D., Hincal A.A., Capan Y., Ponchel G. In vitro studies on enhancing effect of sodium glycocholate on transbuccal permeation of morphine hydrochloride. J. Control. Release 1998, 51:107-113.
84. Lee V.H.L. Protease inhibitors and penetration enhancers as approaches to modify peptide absorption. J. Control. Release 1990, 13:213-223.
85. Smith J., Wood E., Dornish M. Effect of chitosan on epithelial cell tight junctions. Pharm. Res. 2004, 21:43-49.
86. Hsu L.W., Lee P.L., Chen C.T., Mi F.L., Juang J.H., Hwang S.M., Ho Y.C., Sung H.W. Elucidating the signaling mechanism of an epithelial tight-junction opening induced by chitosan. Biomaterials 2012, 33:6254-6263.
87. Dodane V., Amin Khan M., Merwin J.R. Effect of chitosan on epithelial permeability and structure. Int. J. Pharm. 1999, 182:21-32.
88. Schirm E., Tobi H., de Vries T.W., Choonara I., De Jong-van den Berg L.T. Lack of appropriate formulations of medicines for children in the community. Acta Paediatr. 2003, 92:1486-1489.
89. Chaudhary S.A., Shahiwala A.F. Medicated chewing gum-a potential drug delivery system. Expert Opin. Drug Deliv. 2010, 7:871-885.
90. Sheshala R., Khan N., Chitneni M., Darwis Y. Formulation and in vivo evaluation of ondansetron orally disintegrating tablets using different superdisintegrants. Arch. Pharm. Res. 2011, 34:1945-1956.
91. Souto C., Rodriguez A., Parajes S., Martinez-Pacheco R. A comparative study of the utility of two superdisintegrants in microcrystalline cellulose pellets prepared by extrusion-spheronization. Eur. J. Pharm. Biopharm. 2005, 61:94-99.
92. Kianfar F., Chowdhry B.Z., Antonijevic M.D., Boateng J.S. Novel films for drug delivery via the buccal mucosa using model soluble and insoluble drugs. Drug Dev. Ind. Pharm. 2012, 38:1207-1220.
93. Nair A.B., Kumria R., Harsha S., Attimarad M., Al-Dhubiab B.E., Alhaider I.A. In vitro techniques to evaluate buccal films. J. Control. Release 2013, 166:10-21.
94. Dixit R.P., Puthli S.P. Oral strip technology: overview and future potential. J. Control. Release 2009, 139:94-107.
95. Thimmasetty J., Pandey G., Babu P. Design and in vivo evaluation of carvedilol buccal mucoadhesive patches. Pak. J. Pharm. Sci. 2008, 21:241-248.
96. Giovino C., Ayensu I., Tetteh J., Boateng J.S. Development and characterisation of chitosan films impregnated with insulin loaded PEG-b-PLA nanoparticles (NPs): a potential approach for buccal delivery of macromolecules. Int. J. Pharm. 2012, 428:143-151.
97. Boateng J.S., Stevens H.N., Eccleston G.M., Auffret A.D., Humphrey M.J., Matthews K.H. Development and mechanical characterization of solvent-cast polymeric films as potential drug delivery systems to mucosal surfaces. Drug Dev. Ind. Pharm. 2009, 35:986-996.
98. Kohda Y., Kobayashi H., Baba Y., Yuasa H., Ozeki T., Kanaya Y., Sagara E. Controlled release of lidocaine hydrochloride from buccal mucosa adhesive films with solid dispersion. Int. J. Pharm. 1997, 158:147-155.
99. Nafee N.A., Boraie M.A., Ismail F.A., Mortada L.M. Design and characterization of mucoadhesive buccal patches containing cetylpyridinium chloride. Acta Pharm. 2003, 53:199-212.
100. Nafee N.A., Ismail F.A., Boraie N.A., Mortada L.M. Mucoadhesive buccal patches of miconazole nitrate: in vitro/in vivo performance and effect of ageing. Int. J. Pharm. 2003, 264:1-14.
101. Rossi S., Sandri G., Ferrari F., Bonferoni M.C., Caramella C. Buccal delivery of acyclovir from films based on chitosan and polyacrylic acid. Pharm. Dev. Technol. 2003, 8:199-208.
102. Cui Z., Mumper R.J. Buccal transmucosal delivery of calcitonin in rabbits using thin-film composites. Pharm. Res. 2002, 19:1901-1906.
103. Shidhaye S.S., Saindane N.S., Sutar S., Kadam V. Mucoadhesive bilayered patches for administration of sumatriptan succinate. AAPS PharmSciTech 2008, 9:909-916.
104. Repka M.A., Prodduturi S., Stodghill S.P. Production and characterization of hot-melt extruded films containing clotrimazole. Drug Dev. Ind. Pharm. 2003, 29:757-765.
105. Palem C.R., Kumar Battu S., Maddineni S., Gannu R., Repka M.A., Yamsani M.R. Oral transmucosal delivery of domperidone from immediate release films produced via hot-melt extrusion technology. Pharm. Dev. Technol. 2013, 18:186-195.
106. Prodduturi S., Manek R.V., Kolling W.M., Stodghill S.P., Repka M.A. Solid-state stability and characterization of hot-melt extruded poly(ethylene oxide) films. J. Pharm. Sci. 2005, 94:2232-2245.
107. Repka M.A., Gutta K., Prodduturi S., Munjal M., Stodghill S.P. Characterization of cellulosic hot-melt extruded films containing lidocaine. Eur. J. Pharm. Biopharm. 2005, 59:189-196.
108. Morales J.O., McConville J.T. Manufacture and characterization of mucoadhesive buccal films. Eur. J. Pharm. Biopharm. 2011, 77:187-199.
109. Boateng J.S., Auffret A.D., Matthews K.H., Humphrey M.J., Stevens H.N., Eccleston G.M. Characterisation of freeze-dried wafers and solvent evaporated films as potential drug delivery systems to mucosal surfaces. Int. J. Pharm. 2010, 389:24-31.
110. Boateng J.S., Matthews K.H., Auffret A.D., Humphrey M.J., Eccleston G.M., Stevens H.N. Comparison of the in vitro release characteristics of mucosal freeze-dried wafers and solvent-cast films containing an insoluble drug. Drug Dev. Ind. Pharm. 2012, 38:47-54.
111. Ayensu I., Mitchell J.C., Boateng J.S. Development and physico-mechanical characterisation of lyophilised chitosan wafers as potential protein drug delivery systems via the buccal mucosa. Colloids Surf. B Biointerfaces 2012, 91:258-265.
112. Ayensu I., Mitchell J.C., Boateng J.S. Effect of membrane dialysis on characteristics of lyophilised chitosan wafers for potential buccal delivery of proteins. Int. J. Biol. Macromol. 2012, 50:905-909.
113. Kianfar F., Antonijevic M., Chowdhry B., Boateng J.S. Lyophilized wafers comprising carrageenan and pluronic acid for buccal drug delivery using model soluble and insoluble drugs. Colloids Surf. B Biointerfaces 2013, 103:99-106.
114. Kianfar F., Ayensu I., Boateng J.S. Development and physico-mechanical characterization of carrageenan and poloxamer-based lyophilized matrix as a potential buccal drug delivery system. Drug Dev. Ind. Pharm. 2013.
115. Matthews K.H., Stevens H.N., Auffret A.D., Humphrey M.J., Eccleston G.M. Lyophilised wafers as a drug delivery system for wound healing containing methylcellulose as a viscosity modifier. Int. J. Pharm. 2005, 289:51-62.
116. Matthews K.H., Stevens H.N., Auffret A.D., Humphrey M.J., Eccleston G.M. Gamma-irradiation of lyophilised wound healing wafers. Int. J. Pharm. 2006, 313:78-86.
117. Patel D., Smith A.W., Grist N., Barnett P., Smart J.D. An in vitro mucosal model predictive of bioadhesive agents in the oral cavity. J. Control. Release 1999, 61:175-183.
118. Campisi G., Giannola L.I., Florena A.M., De Caro V., Schumacher A., Gottsche T., Paderni C., Wolff A. Bioavailability in vivo of naltrexone following transbuccal administration by an electronically-controlled intraoral device: a trial on pigs. J. Control. Release 2010, 145:214-220.
119. Ciach T., Moscicka-Studzinska A. Buccal iontophoresis: an opportunity for drug delivery and metabolite monitoring. Drug Discov. Today 2011, 16:361-366.
120. Xu Y., Lam J.K., Wong I.C.K., Iessa N. Benefits of buccal midazolam in paediatric patients. Eur. Pharm. Eur. 2012, 65:55-58.
121. Anderson G.D., Saneto R.P. Current oral and non-oral routes of antiepileptic drug delivery. Adv. Drug Deliv. Rev. 2012, 64:911-918.
122. Garnock-Jones K.P. Oromucosal midazolam: a review of its use in pediatric patients with prolonged acute convulsive seizures. Paediatr. Drugs 2012, 14:251-261.
123. McIntyre J., Robertson S., Norris E., Appleton R., Whitehouse W.P., Phillips B., Martland T., Berry K., Collier J., Smith S., Choonara I. Safety and efficacy of buccal midazolam versus rectal diazepam for emergency treatment of seizures in children: a randomised controlled trial. Lancet 2005, 366:205-210.
124. Wilson M.T., Macleod S., O'Regan M.E. Nasal/buccal midazolam use in the community. Arch. Dis. Child. 2004, 89:50-51.
125. Caille G., Spenard J., Lacasse Y., Brennan J. Pharmacokinetics of two lorazepam formulations, oral and sublingual, after multiple doses. Biopharm. Drug Dispos. 1983, 4:31-42.
126. Millikan D., Rice B., Silbergleit R. Emergency treatment of status epilepticus: current thinking. Emerg. Med. Clin. North Am. 2009, 27:101-113. (ix).
127. Onishi H., Sakata O., Masuda K., Machida Y. Novel mucoadhesive oral patch containing diazepam. Drug Dev. Ind. Pharm. 2005, 31:607-613.
128. Ganeshalingam R., O'Connor M. Evidence behind the WHO guidelines: hospital care for children: what is the efficacy of sublingual, oral and intravenous glucose in the treatment of hypoglycaemia?. J. Trop. Pediatr. 2009, 55:287-289.
129. Barennes H., Valea I., Nagot N., Van de Perre P., Pussard E. Sublingual sugar administration as an alternative to intravenous dextrose administration to correct hypoglycemia among children in the tropics. Pediatrics 2005, 116:e648-e653.
130. Achoki R., Opiyo N., English M. Mini-review: management of hypoglycaemia in children aged 0-59months. J. Trop. Pediatr. 2010, 56:227-234.
131. Wheeler M., Birmingham P.K., Dsida R.M., Wang Z., Cote C.J., Avram M.J. Uptake pharmacokinetics of the Fentanyl Oralet in children scheduled for central venous access removal: implications for the timing of initiating painful procedures. Paediatr. Anaesth. 2002, 12:594-599.
132. Walsh S.L., Preston K.L., Stitzer M.L., Cone E.J., Bigelow G.E. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin. Pharmacol. Ther. 1994, 55:569-580.
133. Dahan A., Yassen A., Romberg R., Sarton E., Teppema L., Olofsen E., Danhof M. Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br. J. Anaesth. 2006, 96:627-632.
134. Soyka M. Buprenorphine and buprenorphine/naloxone soluble-film for treatment of opioid dependence. Expert Opin. Drug Deliv. 2012, 9:1409-1417.
135. Kuhlman J.J., Lalani S., Magluilo J., Levine B., Darwin W.D. Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine. J. Anal. Toxicol. 1996, 20:369-378.
136. Geib A.J., Babu K., Ewald M.B., Boyer E.W. Adverse effects in children after unintentional buprenorphine exposure. Pediatrics 2006, 118:1746-1751.
137. Gaulier J.M., Charvier F., Monceaux F., Marquet P., Lachatre G. Ingestion of high-dose buprenorphine by a 4year-old child. J. Toxicol. Clin. Toxicol. 2004, 42:993-995.
138. Kim H.K., Smiddy M., Hoffman R.S., Nelson L.S. Buprenorphine may not be as safe as you think: a pediatric fatality from unintentional exposure. Pediatrics 2012, 130:e1700-e1703.
139. Massimo L., Haupt R., Enrica M. Control of pain with sublingual buprenorphine in children with cancer. Pediatr. Hematol. Oncol. 1985, 2:224.
140. Kraft W.K., Gibson E., Dysart K., Damle V.S., Larusso J.L., Greenspan J.S., Moody D.E., Kaltenbach K., Ehrlich M.E. Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial. Pediatrics 2008, 122:e601-e607.
141. Neutra M.R., Kozlowski P.A. Mucosal vaccines: the promise and the challenge. Nat. Rev. Immunol. 2006, 6:148-158.
142. Kweon M.N. Sublingual mucosa: a new vaccination route for systemic and mucosal immunity. Cytokine 2011, 54:1-5.
143. Song J.H., Nguyen H.H., Cuburu N., Horimoto T., Ko S.Y., Park S.H., Czerkinsky C., Kweon M.N. Sublingual vaccination with influenza virus protects mice against lethal viral infection. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:1644-1649.
144. Cuburu N., Kweon M.N., Hervouet C., Cha H.R., Pang Y.Y., Holmgren J., Stadler K., Schiller J.T., Anjuere F., Czerkinsky C. Sublingual immunization with nonreplicating antigens induces antibody-forming cells and cytotoxic T cells in the female genital tract mucosa and protects against genital papillomavirus infection. J. Immunol. 2009, 183:7851-7859.
145. Campbell D.E. Sublingual immunotherapy for children: are we there yet? Defining its role in clinical practice. Paediatr. Respir. Rev. 2009, 10:69-74. (quiz 74).
146. Bufe A., Roberts G. Specific immunotherapy in children. Clin. Exp. Allergy 2011, 41:1256-1262.
147. Penagos M., Compalati E., Tarantini F., Baena-Cagnani R., Huerta J., Passalacqua G., Canonica G.W. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. Ann. Allergy Asthma Immunol. 2006, 97:141-148.
148. Bufe A., Ziegler-Kirbach E., Stoeckmann E., Heidemann P., Gehlhar K., Holland-Letz T., Braun W. Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study. Allergy 2004, 59:498-504.
149. Rolinck-Werninghaus C., Wolf H., Liebke C., Baars J.C., Lange J., Kopp M.V., Hammermann J., Leupold W., Bartels P., Gruebl A., Bauer C.P., Schnitker J., Wahn U., Niggemann B. A prospective, randomized, double-blind, placebo-controlled multi-centre study on the efficacy and safety of sublingual immunotherapy (SLIT) in children with seasonal allergic rhinoconjunctivitis to grass pollen. Allergy 2004, 59:1285-1293.
150. Khinchi M.S., Poulsen L.K., Carat F., Andre C., Hansen A.B., Malling H.J. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study. Allergy 2004, 59:45-53.
151. Dahl R., Kapp A., Colombo G., de Monchy J.G., Rak S., Emminger W., Rivas M.F., Ribel M., Durham S.R. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J. Allergy Clin. Immunol. 2006, 118:434-440.
152. Durham S.R., Emminger W., Kapp A., Colombo G., de Monchy J.G., Rak S., Scadding G.K., Andersen J.S., Riis B., Dahl R. Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J. Allergy Clin. Immunol. 2010, 125:131-138. (e131-137).
153. Bufe A., Eberle P., Franke-Beckmann E., Funck J., Kimmig M., Klimek L., Knecht R., Stephan V., Tholstrup B., Weisshaar C., Kaiser F. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J. Allergy Clin. Immunol. 2009, 123:167-173. (e167).
154. Wahn U., Tabar A., Kuna P., Halken S., Montagut A., de Beaumont O., Le Gall M. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J. Allergy Clin. Immunol. 2009, 123:160-166. S.S. Group, (e163).
155. Cox L.S., Larenas Linnemann D., Nolte H., Weldon D., Finegold I., Nelson H.S. Sublingual immunotherapy: a comprehensive review. J. Allergy Clin. Immunol. 2006, 117:1021-1035.
156. Hong J., Bielory L. Oralair(R): sublingual immunotherapy for the treatment of grass pollen allergic rhinoconjunctivitis. Expert. Rev. Clin. Immunol. 2011, 7:437-444.
157. Senna G.E., Calderon M., Milani M. Allergy immunotherapy tablet: Grazax(R) for the treatment of grass pollen allergy. Expert. Rev. Clin. Immunol. 2011, 7:21-27.